Occupational asbestos exposure: how to deal with suspected mesothelioma cases—the Dutch approach

Baas, Paul; Hullenaar, N. van 't; Wagenaar, J. P. M.; Kaajan, J. P. G.; Koolen, Marijn; Schrijver, M.; Schlösser, N. J. J.; Burgers, J. A.

doi:10.1093/annonc/mdl021

Cited by 12 publications

(12 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, expertise in palliative care has certainly increased over the past decade. Also, tumours may be diagnosed earlier [10] due to wider knowledge of the effects of asbestos exposure, a less pessimistic view on the clinical management of mesothelioma patients or to better prospects for financial compensation after confirmation of the diagnosis [18].…”

Section: Discussionmentioning

confidence: 99%

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Damhuis¹,

Schroten²,

Burgers³

2011

Eur Respir J

View full text Add to dashboard Cite

Malignant mesothelioma is known for its dismal prognosis and poor response to conventional treatment. Chemotherapy with cisplatin-antifolate combinations recently showed promising response rates and prolonged survival in randomised trials.To assess the impact of this development on clinical practice and survival at a population-based level, treatment patterns and survival trends were studied for patients diagnosed with mesothelioma in the period 1995-2006. 4,731 records were retrieved from the Netherlands Cancer Registry and chemotherapy use and median survival were analysed.For the periods 1995-1998 to 2005-2006, chemotherapy use increased from 8% to 36%. Median survival increased over time from 7.1 months to 9.2 months. For pleural mesothelioma, multivariable analysis demonstrated that survival was poorer for elderly patients and sarcomatoid tumours. The prognostic impact of chemotherapy increased with time. Median survival for chemotherapy treated patients improved from 10.1 months (1995-1998) to 13.1 months (2005)(2006). For peritoneal mesothelioma, median survival was poor (3.9 months) but better for females and younger patients.This study demonstrates that chemotherapy use increased at a national level and coincided with an improvement in survival. The novel chemotherapy regimen appears to be more effective but, due to the observational nature of this study, alternative explanations cannot be excluded.

show abstract

Section: Discussionmentioning

confidence: 99%

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Damhuis¹,

Schroten²,

Burgers³

2011

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…This study involves retrospective analyses of an existing registry comprising 1353 patients with malignant mesothelioma who applied to the Dutch institute for asbestos victims and entered the process for getting financial compensation between 2005 and 2008 (Baas et al , 2006). …”

Section: Methodsmentioning

confidence: 99%

“…The diagnosis of mesothelioma was confirmed by pathologists from the Dutch National Mesothelioma Panel (NMP). When pathological material was not available or insufficient for a confirmed diagnosis by the NMP ( N =62), a final diagnosis was reached by three independent pulmonologists of the Mesothelioma Group of the Dutch Thoracic Society (Baas et al , 2006). …”

Section: Methodsmentioning

confidence: 99%

Prognosis and prognostic factors of patients with mesothelioma: a population-based study

et al. 2012

View full text Add to dashboard Cite

Background:It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management.Methods:We assessed overall (baseline) survival as well as related prognostic variables in a large cohort of 1353 patients with a confirmed diagnosis of malignant mesothelioma between 2005 and 2008.Results:About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. Prognostic variables independently associated with worse survival were: older age (HR=1.04 per year 95% CI (1.03–1.06)), sarcomatoid subtype (HR=2.45 95% CI (2.06–2.90)) and non-pleural localisation (HR=1.67 95% CI (1.26–2.22)).Conclusion:Survival of patients with malignant mesothelioma is still limited and depends highly on patient age, mesothelioma subtype and localisation. In addition, a substantial part of the patients had a long latency time between asbestos exposure and diagnosis.

show abstract

“…The increased incidence and availability of more effective treatment options, have lead to a greater awareness in both patients and doctors to obtain a histopathological confirmation of the disease [1].…”

Section: Introductionmentioning

confidence: 99%

Non-invasive diagnosis of pleural malignancies: The role of tumour markers

et al. 2008

View full text Add to dashboard Cite

Occupational asbestos exposure: how to deal with suspected mesothelioma cases—the Dutch approach

Abstract: Compared with other European countries, this approach, as determined by the IAV and Mesothelioma Group of the DTS, is an effective and rapid way to investigate claims of patients with a possible occupationally related malignant mesothelioma.

Cited by 12 publications

References 2 publications

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Prognosis and prognostic factors of patients with mesothelioma: a population-based study

Non-invasive diagnosis of pleural malignancies: The role of tumour markers

Contact Info

Product

Resources

About